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The relationship and clinical implications of atrial fibrillation (AF) in acute pulmonary embolism (PE) are poorly investigated. We
aimed to analyze clinical characteristics and prognosis in PE patients with paroxysmal AF episode.Methods. From the 391 patients
with PE 31 subjects with paroxysmal AF were selected. This group was compared with patients with PE and sinus rhythm (SR)
and 32 patients with PE and permanent AF. Results. Paroxysmal AF patients were the oldest. Concomitant DVT varies between
groups: paroxysmal AF 32.3%, SR 49.5%, and permanent AF 28.1% (𝑝 = 0.02). The stroke history frequency was 4.6% SR, 12.9%
paroxysmal AF, and 21.9% permanent AF (𝑝 < 0.001). Paroxysmal AF comparing to permanent AF and SR individuals had higher
estimated SPAP (56 versus 48 versus 47mmHg, 𝑝 = 0.01) and shorter ACT (58 versus 65 versus 70ms, 𝑝 = 0.04). Patients with AF
weremore often classified into high-risk group according to revised Geneva score and sPESI than SR patients. In-hospital mortality
was lower in SR (5%) and paroxysmal AF (6.5%) compared to permanent AF group (25%) (𝑝 < 0.001). Conclusions. Patients with
PE-associated paroxysmal AF constitute a separate population. More severe impairment of the parameters reflecting RV afterload
may indicate relation between PE severity and paroxysmal AF episode. Paroxysmal AF has no impact on short-term mortality.
1. Introduction
Atrial fibrillation (AF) is the most common age-related,
sustained cardiac arrhythmia. It accounts for 4% of cases of
arrhythmia in the population older than 60 years and for
8% of cases in patients older than 80 years [1]. AF adversely
affects the prognosis mainly because of thromboembolic
complications such as stroke, development of heart failure,
or progression of preexisting heart failure. The association
between AF and acute PE is complex and not fully elucidated.
The two conditions have some common risk factors, such as
obesity, heart failure, myocardial infarction, and hyperten-
sion [2]. The risk of AF as well as pulmonary embolism (PE)
increases with age. It has not been unequivocally explained
whether the presence of AF in patients with PE affects
their prognosis. So far, it has not been well established
whether AF can lead to episodes of PE due to right-side
intracardiac thrombi formation. Moreover, data concerning
the prognostic significance of paroxysmal AF in patients with
PE are sparse [3]. Paroxysmal AFmay occur as a consequence
of PE due to acute right ventricular (RV) systolic overload
and subsequent right atrial dilation.Therefore, we decided to
explore the hypothesis of whether paroxysmal AF could be
a sign of PE severity and thus a marker of worse prognosis.
We aimed to analyze the significance of paroxysmal AF that
develops in the course of acute PE and to evaluate clinical
characteristics of these patients, performance of the two
prognostic scores for PE, and an impact of paroxysmal AF
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Figure 1: Study flow chart. The characteristics of the study population according to the heart rhythm. AF: atrial fibrillation; PE: pulmonary
embolism; SR: sinus rhythm.
on short- and long-term all-cause mortality compared to
patients in sinus rhythm (SR) and permanent AF.
2. Materials and Methods
The study cohort consisted of 391 consecutive patients with
primary diagnosis of acute PE. Patients were aged 18 years or
older and were hospitalized in the Department of Cardiology
at University Hospital in Białystok, Poland, from January
1, 2004, to December 31, 2013. Their medical records were
retrospectively analyzed. In 344 patients (88%), the diagnosis
of PE was established by thoracic computed tomography
angiography. In the remaining 47 patients (12%), it was
confirmed on the basis of pulmonary ventilation-perfusion
scintigraphy or echocardiography. As a standard procedure
during index hospitalization, color duplex ultrasound of the
lower extremity was performed to assess the presence of
deep vein thrombosis (DVT).The study population was then
divided into three groups (Figure 1):
(a) the sinus rhythm (SR) group included patients in SR
throughout the hospital stay;
(b) the paroxysmal AF group included patients with one
or more episodes of paroxysmal AF documented by
electrocardiogram (ECG) at any time during index
hospitalization. This group included patients in SR
on admission who developed paroxysmal AF during
hospital stay and patients with AF on admission with
sustained SR during subsequent hospital stay;
(c) the permanent AF group included patients with the
diagnosis of permanent AF confirmed by ECG.
There were no patients with valvular AF in the study cohort.
In addition, patients with AF in history who did not develop
AF during hospital stay were excluded.
On admission, demographic and clinical characteristics,
including symptoms, hemodynamic profile, oxygen satu-
ration, length of hospital stay, risk factors for PE, and
comorbidities, were evaluated and compared between the
groups. In addition, the probability of PE was evaluated
retrospectively using the revised version of the Geneva score
rule [4, 5], and the Simplified Pulmonary Embolism Severity
Index (sPESI) was calculated retrospectively. The following
laboratory parameters were also measured on admission:
complete blood count, levels of troponin I, D-dimer, and
estimated glomerular filtration rate (eGFR, using the Mod-
ification of Diet in Renal Disease formula).
Transthoracic echocardiography was performed within
24 hours of admission, and the following parameters were
analyzed: left ventricular ejection fraction (LVEF) estimated
by visual assessment, left atrial dimensions, presence of RV
contractility disturbances, systolic pulmonary artery pressure
determined using the simplified Bernoulli equation (SPAP =
4𝑉maxTR2 +RAP, where𝑉maxTR is themaximal velocity of
tricuspid regurgitant jet and RAP is the estimated right atrial
pressure), pulmonary artery acceleration time, and presence
of thrombi in the right heart cavities or in the pulmonary
artery.
Finally, a standard 12-lead surface electrocardiogram was
recorded to analyze the leading rhythm and the presence of
tachycardia (>100 beats/min).
2.1. Study Outcomes. The primary outcome of the study was
all-cause mortality. Data on all-cause in-hospital mortality
were retrieved frommedical records.The long-term outcome
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Table 1: Characteristics and outcome of the patients with pulmonary embolism stratified for the presence of the sinus rhythm (SR),
paroxysmal atrial fibrillation (paroxysmal AF), and permanent atrial fibrillation (permanent AF).
SR (𝑛 = 303),
Me (Q1–Q3) or %
Paroxysmal AF (𝑛 = 31),
Me (Q1–Q3) or %
Permanent AF (𝑛 = 32),
Me (Q1–Q3) or % 𝑝 value
Age, years 64 (49–76)a,b 78 (69–82)b 74 (67–79)a <0.001
Males 44.2% 32.3% 43.8% 0.44
Obesity (BMI ≥ 30) 37.9% 41.7% 21.7% 0.27
Overweight (BMI 25–30) 25.0% 16.7% 26.1% 0.65
Current smoker 13,3% 7.7% 16.7% 0.62
Ex-smoker 23.8% 7.7% 25% 0.17
Length of hospital stay, days 9.0 (7–12) 10.0 (8–13) 9.0 (4–12) 0.13
Comorbidities
Cardiovascular disease 12.9% 13.4% 15.6% 0.57
Arterial hypertension 54.8% 58.1% 56.3% 0.9
Diabetes 14.5% 16.1% 12.5% 0.92
Chronic obstructive pulmonary disease 5.3% 9.7% 3.1% 0.49
History of stroke 4.6% 12.9% 21.9% <0.001
Mortality
In-hospital mortality 5% 6.5% 25% <0.001
Me (Q1–Q3) or%: data presented as a median and interquartile range or a percent of the group.
a𝑝 value < 0.01; b𝑝 value < 0.001.
BMI: body mass index (kg/m2).
of the study cohort was retrieved from a national death
registry database provided by the Polish Ministry of Home
Affairs. A censored date of October 13, 2015, was determined
to allow a minimum follow-up of 20 months for living
patients (range, 20–178 months). In addition, we decided to
analyze one-year survival.
The study protocol was approved by local ethics committee.
2.2. Statistical Analysis. In statistical analysis, categorical
variables were compared using the chi-square test of inde-
pendence. Normality of distribution was evaluated by the
Kolmogorov-Smirnov test with the Lilliefors correction and
the Shapiro-Wilk test. There was nonnormal distribution of
continuous variables.The quantitative parameters were char-
acterized by a median and quartiles and the nominal param-
eters using percentages. The nonparametric Kruskal-Wallis
test with post hoc test was used to compare quantitative vari-
ables without normal distribution between the three groups.
Survival was estimated using the Kaplan-Meier method
for each rhythm group. Differences between survival curves
in the three groups were evaluated using the chi-square test.
For all tests, a 𝑝 value of less than 0.05 was considered
statistically significant. Statistical analysis was performed
using the Statistica 12.0 software (StatSoft, Inc., Tulsa, USA).
3. Results
The clinical characteristics, outcome, laboratory parameters,
and risk score profiles of the study population stratified
according to SR, paroxysmal AF, and permanent AF are
shown inTables 1–3. Of 391 patients with confirmed diagnosis
of PE, we identified 63 individuals (16%) with AF.Thirty-one
patients (7.9%) were classified as having paroxysmal AF, and
15 of them (48%) reported a history of AF. In 32 patients
(8.2%), permanent AF was confirmed. Nine patients were
excluded from the study as having cardiac rhythm other than
sinus or AF (Figure 1).
Patients with paroxysmal AF were a median of 13 years
older than patients in SR and a median of 4 years older than
those with permanent AF (Table 1).There were no differences
in sex distribution or in clinical symptoms on admission
between the three groups (Tables 1 and 2).
The frequency of stroke in history significantly increased
from 4.6% in patients with SR to 12.9% in those with
paroxysmal AF and to 21.9% in those with permanent AF
(Table 1).
ConcomitantDVTduring index hospitalization occurred
significantly less often in patients with paroxysmal AF com-
pared with the SR group. However, the proportion of patients
with DVT was the lowest in patients with permanent AF
(Table 2). The hemodynamic profile on admission revealed
a higher prevalence of tachycardia (>100 beats/min) in both
AF groups than in the SR group, with the highest proportion
of patients with tachycardia in the group with paroxysmal AF
(Table 2).
In the analysis of laboratory parameters, the only differ-
ence between the three groups was shown for eGFR: it was
significantly lower in patients with paroxysmal as well as per-
manent AF as comparedwith those with SR (Table 3). Among
echocardiographic parameters, patients with paroxysmal AF
had the highestmedian value of estimated systolic pulmonary
artery pressure and the shortest median pulmonary artery
acceleration time (Table 3). On the other hand, patients with
paroxysmal AF had significantly higher median values of left
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Table 2: Comparison of the admission clinical parameters, Geneva risk score results, and sPESI score values in patients with sinus rhythm
(SR), paroxysmal atrial fibrillation (paroxysmal AF), and permanent atrial fibrillation (permanent AF).
SR (𝑛 = 303),
Me (Q1–Q3) or %
Paroxysmal AF (𝑛 = 31),
Me (Q1–Q3) or %
Permanent AF (𝑛 = 32),
Me (Q1–Q3) or % 𝑝 value
PE symptoms
Syncope 19.0% 26.7% 10% 0.25
Chest pain 30.0% 36.7% 30% 0.75
Dyspnea 86.6% 96.7% 79.3% 0.14
Hemoptysis 2.0% 0 6.3% 0.2
Cough 8.3% 6.7% 16.7% 0.28
PE associated with DVT 49.5% 32.3% 28.1% 0.02
Risk factors
Immobilization 19.1% 19.4% 34.4% 0.13
Malignancy 17.8% 9.7% 18.8% 0.5
Pregnancy/delivery 3.3% 0 0 0.34
Recurrent PE 6.6% 0 3.1% 0.26
The revised Geneva risk
score: clinical probability 0.04
Low 17.3% 16.1% 12.5%
Intermediate 76.1% 64.5% 68.8%
High 6.6% 19.4% 18.8%
sPESI score ≥ 1 56.2% 86.2% 82.6% <0.001
Hemodynamic profile on
admission
Heart rate, beats per minute 89.5 (78–103)a 99 (78–124) 101 (81–122)a 0.01
Tachycardia (>100
beats/minute) 32.0% 54.8% 50% 0.08
Systolic blood pressure,
mmHg 130 (115–145) 125 (106–145) 126 (109–142) 0.6
Oxygen saturation, % 95 (92–97) 95 (90–97) 95 (90–96) 0.17
Me (Q1–Q3) or%: data presented as a median and interquartile range or a percent of the group.
a𝑝 value 𝑝 = 0.05.
DVT: deep vein thrombosis; PE: pulmonary embolism.
Table 3: Comparison of the baseline laboratory and echocardiographic parameters in patients with sinus rhythm (SR), paroxysmal atrial
fibrillation (paroxysmal AF), and permanent atrial fibrillation (permanent AF).
SR (𝑛 = 303),
Me (Q1–Q3) or %
Paroxysmal AF (𝑛 = 31),
Me (Q1–Q3) or %
Permanent AF (𝑛 = 32),
Me (Q1–Q3) or % 𝑝 value
Biochemical parameters
eGFR, ml/min/1.73m2 76 (59–93)c,d 63 (51–83)d 53 (33–79)c <0.001
Troponin I, ng/ml 0.066 (0.01–0.4) 0.11 (0.046–0.42) 0.036 (0.008–0.34) 0.3
D-dimer, ng/ml 5.6 (3–12.0) 10.6 (3.5–19.9) 11 (4.2–15.1) 0.3
Hemoglobin, g/dl 12.7 (11.4–14) 13.2 (11.4–14.7) 12.6 (10.7–15) 0.58
Echocardiography
LVEF, % 60 (50–60)c 55 (50–60)b 48 (30–55)b,c <0.001
LA, cm 3.7 (3.3–4.0)a,c 3.9 (3.6–4.4)a,b 4.4 (4.2–5.1)b,c <0.001
SPAP, mmHg 47 (37–59)b 56 (47–70)b 48 (45–59) 0.01
ACT, ms 70 (54–95)a 58 (51–65)a 65 (55–80) 0.04
RV wall contractility disturbances 58.4% 77.4% 67.9% 0.09
Thrombus in RA/RV 5.2% 10% 14.3% 0.11
Me (Q1–Q3) or%: data presented as a median and interquartile range or a percent of the group
a𝑝 value < 0.05; b𝑝 value < 0.01; c𝑝 value < 0.001; d𝑝 value 𝑝 = 0.05.
ACT: acceleration time; GFR: glomerular filtration rate; LA: left atrium; LVEF: left ventricular ejection fraction; SPAP: systolic pulmonary artery pressure; RV:
right ventricle.

























Figure 2: The Kaplan-Meyer curves in PE patients comparing
survival between three groups: the sinus rhythm (SR) group, parox-
ysmal atrial fibrillation (paroxysmal AF) group, and permanent
atrial fibrillation (permanent AF) group.
ventricular ejection fraction and smaller left atrial diameter
compared with the permanent AF group (Table 3). Patients
with AF also showed a tendency to have a higher rate of right
heart thrombosis. Furthermore, this rate tended to be higher
in patientswith permanent than in thosewith paroxysmalAF,
although the difference was not significant.
The retrospective analysis of the probability of PE, using
the revised version of the Geneva score rule, showed sig-
nificant differences between the three groups. Patients with
both types of AF were more likely to be classified into the
high-probability group than patients with SR. The high-
probability group included more patients with paroxysmal
thanwith permanentAF (Table 2).The same trendwas shown
for the sPESI. Eighty-six percent (86.2%) of patients with
paroxysmal AF group had a sPESI of 1 or higher, compared
with 82.6% of patients with permanent AF and 56.2% of those
with SR (Table 2).
Regarding in-hospital mortality, it was significantly lower
in patients with SR and paroxysmal AF (5% and 6.5%, resp.)
compared to patients with permanent AF (25%) (Table 1).The
results of the Kaplan-Meier survival analysis are presented
in Figure 2. There was a trend towards worse survival in
patients with paroxysmal AF in comparison with those with
permanent AF and particularly those with SR, although the
differences were not significant (𝑝 = 0.067).
4. Discussion
In this study, we found that, among patients with an
acute episode of PE, those who develop paroxysmal AF on
admission or during hospital stay have a different clinical
presentation than those in SR or with permanent AF. We
performed a detailed analysis of our baseline data, including
the results of an echocardiographic examination of patients
with paroxysmal AF and those with permanent AF. The
data suggest that paroxysmal AF may be a sign of PE
severity and may affect long-term prognosis. To date, no
studies have been published that would focus specifically on
paroxysmal AF in patients with PE. Regarding the analyzed
variables, patients with paroxysmal AF are situated distinctly
in between patients with SR and permanent AF. Interestingly,
therewere no significant differences between the three groups
in terms ofmost comorbidities, risk factors, and symptoms of
PE on admission, as well as the length of hospital stay.
The hypothesis that PE may provoke AF is grounded
on a pathophysiological basis. Sudden RV systolic overload
results in an increase of right atrial pressure, which in
turn leads to atrial arrhythmias. In the present study, in
an echocardiographic examination, patients with paroxysmal
AF demonstrated the indirect signs of RV overload such
as the shortest artery acceleration time and the highest
estimated systolic pulmonary artery pressure compared with
patients in SR or in those with permanent AF. Patients with
paroxysmal AF also showed a trend towards the highest
troponin I concentrations, although the differences with the
other groups were not significant. Such results have never
been demonstrated before.
In our study population the prevalence of AF was higher
than in general population [1] and paroxysmal AF comprised
nearly half of cases of AF. Depending on the inclusion
criteria [3, 6, 7], the prevalence of AF in patients with
PE was reported between 9% and 44%. Some investigators
included both patients with AF on admission, as shown on
an electrocardiogram, as well as those with a history of AF
without AF at index hospitalization in a single AF group
[6, 8]. Most authors did not differentiate AF into paroxysmal,
persistent, and permanent [3, 6, 8–10]. There have been only
a few studies investigating the relationship between PE and
paroxysmal AF [6, 9–11]. In one study [5] the proportion
of patients with paroxysmal AF was comparable. In another
study paroxysmal AF was identified in 13% of participants
[10]. The difference in the prevalence of paroxysmal AF was
probably due to the design of the study, which investigated
the quality of oral anticoagulation in a cohort of patients with
a history of venous thromboembolism (VTE) at any time of
their life. The problem of inefficient anticoagulation has been
raised previously [12]. There were no data concerning the
acuteness of a VTE episode and a temporal sequence of VTE
and AF events.
AF may be not only a consequence of PE but also a
risk factor for PE. It induces the prothrombotic state due to
activation of the coagulation cascade and platelets [13]. Lack
of atrial contraction results in blood stasis and possibility
of thrombus formation in both atria, particularly in their
appendages [14, 15]. Data concerning the association between
PE, AF, right heart thrombus formation, and prognosis have
been recently reported [5, 16]. Surprisingly, the authors did
not find an association between AF and RHT. We observed
a tendency to the higher prevalence of RHT both in patients
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with paroxysmal AF and in those with permanent AF, but the
difference did not reach significance.
Another indirect argument supporting the hypothesis
about a causal relationship between AF and subsequent PE is
the observation concerning lower frequency of concomitant
DVT in patients with unprovoked PE [9–11]. In one study
both paroxysmal AF and nonparoxysmal AF were associated
with the increased risk of VTE (particularly PE), with the
same statistical significance. In another study permanent AF
was more common than paroxysmal AF in patients with
isolated PE [10]. In our study in patients with SR, concomitant
DVT was detected significantly more often than in patients
with paroxysmal AF but the lowest frequency of concomitant
DVT was discovered in patients with permanent AF.
Data on the effect of AF on outcome in patients with acute
PE are rare and unequivocal. In some studies, negative impact
on mortality was demonstrated [3, 6]. Some investigators did
not find any association between AF in patients with PE and
prognosis of these patients [10, 17]. Also, it is not known
whether AF is an independent risk factor for mortality or
whether it occurs as a consequence of PE severity or the
presence of comorbidities. Furthermore, in the majority of
studies concerning patients with PE, the effect of AF on
survival was analyzed without differentiation of AF patterns.
There are several possible explanations why patients with
paroxysmal AF in our study had worse echocardiographic
parameters reflecting RV afterload and the highest pro-
portion of an sPESI score of 1 or higher both indicating
worse prognosis, but without impact on in-hospitalmortality.
One possibility is that both the signs of RV dysfunction on
echocardiogram and sPESI help identify low-risk patients
more accurately than high-risk patients [18–20]. Another
possibility is that, in patients with SR and paroxysmal AF,
there were two important prognostic makers whose median
values were within the normal range: LVEF and eGFR [21].
Another important issue that emerged in our study
relates to the usefulness of risk scores in PE patients with
paroxysmal AF. We decided to verify the Geneva score
rule, calculated retrospectively on admission, as well as the
sPESI score. Their prognostic value in long-term follow-up
was demonstrated among patients with confirmed PE [22,
23]. In our study the high-probability group included the
highest percentage of patients with paroxysmal AF compared
with the other groups. This probably resulted from older
age and the prevalence of tachycardia (>100 beats/min) on
admission in patients with paroxysmal AF. Despite the results
of both scales, the in-hospital mortality rate of patients with
paroxysmal AF was rather low, in contrast to patients with
permanent AF in whom the rate was high.
The sPESI score was initially developed for 30-day risk
assessment in patients with PE [24]. In our PE patients
with paroxysmal AF, sPESI showed better prognostic value
for long-term survival than for in-hospital outcome. Again
it is possible that the presence of tachycardia typical for a
paroxysmal episode of AF may constitute a confounding
variable.Thismaymean that, in patients with PE complicated
by a paroxysmal episode of AF, the current scales may
overestimate short-term risk.
Our study has several strengths and limitations.Themain
limitation is the retrospective analysis of the patient’s data. As
a result, we have incomplete information concerning prior
anticoagulation in patients with AF. On the other hand, the
strengths of our study include a large number of patients from
the same center, well-validated in-hospital data, and long-
term follow-up.
5. Conclusions
Our study showed that individuals with paroxysmal AF
constitute a separate population of patients than patients with
PE and SR or those with permanent AF. Worse echocardio-
graphic parameters reflecting RV afterload may indicate a
causal association between the severity of PE and an episode
of paroxysmal AF. This factor has significance but only for
long-term prognosis. Further studies on a larger population
of patients with PE are needed to determine the prognostic
significance of AF types in patients with PE as well as the
accuracy of PE risk scales in patients with different AF
patterns.
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